Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial)
Satralizumab,an Anti-IL-6 Receptor Antibody, in the Treatment of Pulmonary Arterial Hypertension; Safety and Efficacy Evaluation in Japan -Multicenter, Investigator-sponsored Trial-
Sponsor: Chugai Pharmaceutical
This PHASE2 trial investigates Pulmonary Arterial Hypertension and is currently ongoing. Chugai Pharmaceutical leads this study, which shows 12 recorded versions since 2022 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
12 versions recorded-
Oct 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Oct 2025 [monthly]
Active Not Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 7 earlier versions
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Apr 2024 [monthly]
Recruiting PHASE2
-
Sep 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Jul 2023 — Sep 2023 [monthly]
Recruiting PHASE2
-
May 2023 — Jul 2023 [monthly]
Recruiting PHASE2
-
Mar 2023 — May 2023 [monthly]
Recruiting PHASE2
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE2
First recorded
Jul 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chugai Pharmaceutical
- International University of Health and Welfare
- Japan Agency for Medical Research and Development
- Keio University
For direct contact, visit the study record on ClinicalTrials.gov .